Kandeel, M.; Morsy, M.A.; Abd El-Lateef, H.M.; Marzok, M.; El-Beltagi, H.S.; Al Khodair, K.M.; Albokhadaim, I.; Venugopala, K.N.
The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients. Processes 2023, 11, 398.
https://doi.org/10.3390/pr11020398
AMA Style
Kandeel M, Morsy MA, Abd El-Lateef HM, Marzok M, El-Beltagi HS, Al Khodair KM, Albokhadaim I, Venugopala KN.
The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients. Processes. 2023; 11(2):398.
https://doi.org/10.3390/pr11020398
Chicago/Turabian Style
Kandeel, Mahmoud, Mohamed A. Morsy, Hany M. Abd El-Lateef, Mohamed Marzok, Hossam S. El-Beltagi, Khalid M. Al Khodair, Ibrahim Albokhadaim, and Katharigatta N. Venugopala.
2023. "The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients" Processes 11, no. 2: 398.
https://doi.org/10.3390/pr11020398
APA Style
Kandeel, M., Morsy, M. A., Abd El-Lateef, H. M., Marzok, M., El-Beltagi, H. S., Al Khodair, K. M., Albokhadaim, I., & Venugopala, K. N.
(2023). The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients. Processes, 11(2), 398.
https://doi.org/10.3390/pr11020398
